Executive Vice President
Janssen Pharmaceuticals, the maker of the anti-psychotic drug Risperdal, is set to face another wave of trials coming in the fall and early spring over their alleged illegal marketing practices of the drug. Three trials have already been decided to date, the first two resulting in verdicts against Janssen, with one resulting in a $2.5 million verdict for the plaintiff. The third case that was previously resolved ended in an undisclosed settlement agreement. Risperdal litigation has been rapidly expanding, with over 200 cases being filed this year. The next two cases are set for trial in October, and about 10 cases are reportedly in pre-trial discovery, with expected trial dates for early to mid-2016.
Plaintiff Support offers a variety of settlement funding services to help plaintiffs and attorneys during and after a personal injury case. Learn more about how we can help you.